MARKET

ORKA

ORKA

Oruka Therapeutics Inc
NASDAQ
33.05
+1.63
+5.19%
After Hours: 33.05 0 0.00% 17:43 02/06 EST
OPEN
32.03
PREV CLOSE
31.42
HIGH
33.43
LOW
31.38
VOLUME
504.90K
TURNOVER
--
52 WEEK HIGH
36.51
52 WEEK LOW
5.49
MARKET CAP
1.60B
P/E (TTM)
-13.9894
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), 10x Genomics (TXG) and Oruka Therapeutics (ORKA)
TipRanks · 2d ago
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
TipRanks · 2d ago
BTIG Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)
TipRanks · 4d ago
Weekly Report: what happened at ORKA last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at ORKA last week (0119-0123)?
Weekly Report · 01/26 09:01
Weekly Report: what happened at ORKA last week (0112-0116)?
Weekly Report · 01/19 09:01
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Nuvation Bio (NUVB)
TipRanks · 01/15 12:31
Oruka Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 01/13 13:59
More
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Webull offers Oruka Therapeutics Inc stock information, including NASDAQ: ORKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORKA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORKA stock methods without spending real money on the virtual paper trading platform.